U.S. Healthcare Services Stock News

NasdaqGS:UPB
NasdaqGS:UPBBiotechs

Why Upstream Bio (UPB) Is Up 12.2% After JPM Debut And VALINAT Hopes

In early January 2026, Upstream Bio, Inc. presented at the 44th Annual J.P. Morgan Healthcare Conference, while analysts initiated and upgraded coverage around its asthma candidate verekitug and the upcoming Phase 2 VALINAT readout. The combination of growing physician enthusiasm for long-acting TSLP inhibition and expectations for the VALINAT data has sharpened investor focus on Upstream Bio’s clinical pipeline. Against this backdrop, we’ll examine how physician interest in verekitug and...
NasdaqGS:BBSI
NasdaqGS:BBSIProfessional Services

Assessing Barrett Business Services (BBSI) Valuation After New Employee File Cabinet HR Tech Launch

What the new Employee File Cabinet launch means for BBSI shareholders Barrett Business Services (BBSI) has rolled out its Employee File Cabinet HRIS module within the BBSI Client Portal, built with Box, giving clients a secure, centralized hub for key HR documents. The launch highlights BBSI’s ongoing push to consolidate HR workflows into a single portal experience. The company points to potential benefits around compliance, time savings, and employee access to their own documents. See our...
NasdaqGS:CVGW
NasdaqGS:CVGWFood

Calavo Growers (CVGW) Margin Turnaround Challenges Cautious Earnings Narratives

Calavo Growers (CVGW) just wrapped up FY 2025 with Q4 revenue of US$124.7 million and basic EPS of US$0.21. Trailing 12 month revenue came in at US$648.4 million and EPS at US$1.11, supported by a trailing net profit margin of 3.1% versus 1.0% in the prior year. Over the last few quarters, revenue has ranged from US$154.4 million to US$190.5 million with quarterly EPS between US$0.21 and US$0.38. This points to a picture of improving profitability that puts margins, rather than top line...
NYSE:DEI
NYSE:DEIOffice REITs

Is Douglas Emmett (DEI) Now Attractive After Prolonged Share Price Weakness And Office Market Concerns

If you are wondering whether Douglas Emmett is priced attractively today, or if the share price still does not reflect its underlying real estate assets, this article explains what the current market value might be telling you. The stock recently closed at US$10.97, with returns of a 1.6% decline over 7 days, a 4.8% decline over 30 days, a 0.9% decline year to date, a 32.8% decline over 1 year and a 51.5% decline over 5 years. This performance may have changed how investors view its risk and...
NYSE:GS
NYSE:GSCapital Markets

Goldman Sachs Group (GS) Earnings Rebound And 27.4% Margin Test Moderate Growth Narratives

Goldman Sachs FY 2025 Earnings Snapshot Goldman Sachs (GS) closed out FY 2025 with fourth quarter revenue of US$15.6 billion and basic EPS of US$14.27 on net income of US$4.4 billion, setting the tone for how investors are reading the latest numbers. Over the past six reported quarters, the bank has seen quarterly revenue move from US$12.3 billion in Q3 2024 to US$13.5 billion in Q4 2024 and then to US$15.6 billion in Q4 2025, while basic EPS shifted from US$8.52 to US$12.14 to US$14.27 over...
NasdaqCM:MREO
NasdaqCM:MREOBiotechs

Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift

Mereo BioPharma Group recently reported that its Phase 3 Orbit and Cosmic trials of setrusumab in osteogenesis imperfecta missed their primary fracture reduction endpoints but achieved strong statistical improvements in bone mineral density, while also updating investors that its approximately US$41,000,000 cash balance at 31 December 2025 is expected to fund operations to mid-2027. Alongside reassessing the future of setrusumab with partner Ultragenyx, Mereo is pushing ahead with a single...